An interesting question is also whether lymphomas with c-Rel gain are particularly susceptible to c-Rel inhibition or whether they display other specific vulnerabilities due to direct of indirect consequences of c-Rel gain that could be exploited therapeutically. The gene discussed is REL; the disease is lymphoma.